Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABSW), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of products from its proprietary immunotherapy platform to produce targeted human polyclonal antibodies. The company leverages transchromosomic cattle genetically designed to produce human antibodies in response to an antigen. With a breakthrough therapy designation from the FDA, SAB-176 targets influenza strains, demonstrating sustained neutralization activity. The company's DiversitAb platform enables the production of fully human target-specific biologics for various therapeutic areas.
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announces CEO's presentation at 35th Annual Piper Sandler Healthcare Conference to discuss the development of hIgG for type 1 diabetes. The event aims to gather industry leaders and investors for trend analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics appoints Michael G. King Jr. as Chief Financial Officer. King brings over 25 years of experience as a biotech equity research analyst and senior advisor. He will replace Russell Beyer, who will remain a senior advisor until the end of the year. King's expertise will contribute to SAB's goal of developing disease-modifying treatments for type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics receives approval for Phase 1 clinical study of SAB-142 in Australia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SAB Biotherapeutics announces closing of $7.5 million financing and appointment of Andrew Moin to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics secures $130 million in funding to support clinical advancement of SAB-142, a potential disease-modifying treatment for type 1 diabetes (T1D)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics reports Q2 2023 financial results and provides company update. Highlights include positive data for SAB-142 in Type 1 Diabetes and FDA approval for sections of New Animal Drug Application. Cash and cash equivalents at $7.8 million. R&D expenses decrease to $3.7 million. Net loss of $6.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SAB Biotherapeutics will be hosting its Virtual 2023 Annual R&D Day on June 14, 2023, providing an overview of its novel immunotherapy platform and portfolio progress. Recent breakthrough therapy and fast track designations will be discussed, along with important data validating a Type 1 diabetes therapeutic candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of SAB BIOTHERAPEUTICS (SABSW)?
The current stock price of SAB BIOTHERAPEUTICS (SABSW) is $0.03 as of February 25, 2025.
What is SAB Biotherapeutics Inc. focused on?
SAB is focused on developing and commercializing a portfolio of products from its immunotherapy platform to produce human polyclonal antibodies.
What is the novel DiversitAb platform used by SAB?
The DiversitAb platform enables the rapid production of targeted human polyclonal antibodies using transchromosomic cattle.
What is SAB-176 and its significance?
SAB-176 is a biologic targeting influenza strains with sustained neutralization activity and has received FDA Breakthrough Therapy Designation.
What is the focus of SAB's clinical programs?
SAB focuses on disease-modifying therapeutic approaches, such as SAB-142 targeting type 1 diabetes, aiming to prevent disease progression.
What are some key achievements of SAB in the clinical trials?
SAB has completed Phase 2 studies demonstrating the efficacy of its products in challenging influenza models, paving the way for potential breakthrough treatments.
How does SAB's immunotherapy platform differ from traditional methods?
SAB's platform leverages transchromosomic cattle to produce fully human antibodies, eliminating the need for convalescent plasma or human donors.
What is the significance of SAB's approach to human-specific biologics?
SAB's approach allows the production of highly targeted, high-potency, fully human IgGs to address serious unmet needs in various human diseases.
How does SAB aim to contribute to the field of immunotherapy?
SAB is committed to pioneering disease-modifying therapies, focusing on advancing treatments for immune and autoimmune disorders like type 1 diabetes.
How does SAB prioritize research and development efforts?
SAB's research and development efforts are geared towards developing safe, effective therapies with differentiated safety and immunogenicity profiles, aiming to change treatment paradigms in various diseases.
What future milestones can we expect from SAB?
SAB is on track to achieve upcoming milestones, including a Phase 2B trial for its lead candidate, SAB-142, and continued advancements in pioneering disease-modifying therapies.
SAB BIOTHERAPEUTICS INC